rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2000-151rsp-486Research ArticleСтатьиArticlesЦЕЛЕБРЕКС - ПЕРВЫЙ СПЕЦИФИЧЕСКИЙ ИНГИБИТОР ЦОГ-2: НОВЫЕ ДАННЫЕCELEBREX: THE FIRST SPECIFIC INHIBITOR OF COX-2: NEW DATANassonovE LNassonovE L
Кафедра ревматологии
Kafedra revmatologii
-200015082000384№4 (2000)33Copyright © Nassonov E.L., 20002000Nassonov E.L.Nassonov E.L.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/486References<div><p>Насонов Е.Л., Цветкова Е.С., Тов H.JT. Селективные ингибиторы циклооксигеназы-2: новые перспективы лечения заболеваний человека. Тер. Архив, 1998, 5, 8-14.</p><p>Насонов Е.Л. Целекоксиб - первый специфический ингибитор циклооксигеназы 2. Русский медицинский журнал, 1999, 12, 580-585.</p><p>Насонов Е.Л. Специфические ингибиторы циклооксигеназы (ЦОГ)-2, решенные и не решенные проблемы. Клин, фармакология и терапия, 2000, 1, 57-64.</p><p>Насонов Е.Л. Нестероидные противовоспалительные препараты. (Перспективы применения в медицине), Москва, 2000, 262.</p><p>Akdamar К., Ertan A., Agarwal N.M., et al. Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest. Endoscopy, 1986,32,78-80.</p><p>Bensen W.G., Fiectner J.J., McMiller J.I., et al. T reatment of osteoarthritis with celecoxib. A cycloox- ygenase-2 inhibitors: a randomized controlled trial. Mayo Clin. Proc., 1999, 74, 1095-1105.</p><p>DuBois R.N., Abramson S.B., Crofford L., et al. Cyclooxygenase in biology and medicine. FASEB J., 1998, 12, 1063-1073.</p><p>Emery P., Zeidler H., Kvien Т.К., et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet, 1999, 354, 2106-2111.</p><p>Feldman М., McMachon A.T. Do cyclooxigenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointerstinal toxicitv. Ann. Intern. Med., 2000, 132, 134-143.</p><p>Geis G.S., Fitzgerald G. A., Karim A., et al. A comparative study of platelet function in subjects receiving either celecoxib, a specific COX-2 inhibitor, or ibuprofen, a nonspecific inhibitor of cyclooxygenase. XV European League Against Rheumatism (EULAR) Congress, Nice, June 2000 (abst.).</p><p>Goldstein J., Whelton A., Faich G. Celecoxib safety and tolerability profile: GI and beyond, with perspectives on celecoxib cardiovascular effects.Satelliye Symposium at the XV European League Against Rheumatism (EULAR) Congress, Nice, June 2000.</p><p>Hawkey C.J. COX-2 inhibitors. Lancet, 1999, 353, 307-314.</p><p>IhmakiТ., VarisK.,Siurala M. Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Scand. J. Gastroenterol., 1979, 14, 801-812.</p><p>Kaplan-Machiis B., Kiostermeyer B.S. The cycloox- iygenase-2 inhibitors: safety and effectiveness. Ann. Pharmacotherapy, 1999, 33, 979-988.</p><p>Kolondy A.L. Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of rheumatoid arthritis. J. Rheumatol., 1988, 15, 1205-1211.</p><p>Lipsky P.E., Abramson S.B., Crofford L., et al. The classification of cyclooxygenase inhibitors. J. Rheumatol., 1998, 25, 2298-2302.</p><p>Needleman P., Isacson P.C. The discovery and function of COX-2. J. Rheumatol., 1997, 24, 6-7.</p><p>Peterson W.L.,Cryer В.COX-1-SparingNSAIDs-is theenthusiasm justified? JAMA, 1999,282,1961-1963.</p><p>Singh G. Celecoxib use in patients: the spectrum and everyday experience. Satellite Symposium at the XV European League Against Rheumatism (ELTLAR) Congress, Nice, June 2000.</p><p>Singh G., Ramey D.R., Triadafilopoulos Experience with selective COX-2 inhibitors: safety profile in over 780000 patient years of use. XV European League Against Rheumatism (EULAR) Congress, Nice, June 2000 (abst.).</p><p>Simon L.S., Weaver A.L., Graham D.Y., et al. Antiinflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA, 1999, 282, 1921-1928.</p><p>Vane J. Towards a better aspirin. Nature, 1994, 367, 215-216.</p></div><br /><div><p>Насонов Е.Л., Цветкова Е.С., Тов H.JT. Селективные ингибиторы циклооксигеназы-2: новые перспективы лечения заболеваний человека. Тер. Архив, 1998, 5, 8-14.</p><p>Насонов Е.Л. Целекоксиб - первый специфический ингибитор циклооксигеназы 2. Русский медицинский журнал, 1999, 12, 580-585.</p><p>Насонов Е.Л. Специфические ингибиторы циклооксигеназы (ЦОГ)-2, решенные и не решенные проблемы. Клин, фармакология и терапия, 2000, 1, 57-64.</p><p>Насонов Е.Л. Нестероидные противовоспалительные препараты. (Перспективы применения в медицине), Москва, 2000, 262.</p><p>Akdamar К., Ertan A., Agarwal N.M., et al. Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest. Endoscopy, 1986,32,78-80.</p><p>Bensen W.G., Fiectner J.J., McMiller J.I., et al. T reatment of osteoarthritis with celecoxib. A cycloox- ygenase-2 inhibitors: a randomized controlled trial. Mayo Clin. Proc., 1999, 74, 1095-1105.</p><p>DuBois R.N., Abramson S.B., Crofford L., et al. Cyclooxygenase in biology and medicine. FASEB J., 1998, 12, 1063-1073.</p><p>Emery P., Zeidler H., Kvien Т.К., et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet, 1999, 354, 2106-2111.</p><p>Feldman М., McMachon A.T. Do cyclooxigenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointerstinal toxicitv. Ann. Intern. Med., 2000, 132, 134-143.</p><p>Geis G.S., Fitzgerald G. A., Karim A., et al. A comparative study of platelet function in subjects receiving either celecoxib, a specific COX-2 inhibitor, or ibuprofen, a nonspecific inhibitor of cyclooxygenase. XV European League Against Rheumatism (EULAR) Congress, Nice, June 2000 (abst.).</p><p>Goldstein J., Whelton A., Faich G. Celecoxib safety and tolerability profile: GI and beyond, with perspectives on celecoxib cardiovascular effects.Satelliye Symposium at the XV European League Against Rheumatism (EULAR) Congress, Nice, June 2000.</p><p>Hawkey C.J. COX-2 inhibitors. Lancet, 1999, 353, 307-314.</p><p>IhmakiТ., VarisK.,Siurala M. Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Scand. J. Gastroenterol., 1979, 14, 801-812.</p><p>Kaplan-Machiis B., Kiostermeyer B.S. The cycloox- iygenase-2 inhibitors: safety and effectiveness. Ann. Pharmacotherapy, 1999, 33, 979-988.</p><p>Kolondy A.L. Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of rheumatoid arthritis. J. Rheumatol., 1988, 15, 1205-1211.</p><p>Lipsky P.E., Abramson S.B., Crofford L., et al. The classification of cyclooxygenase inhibitors. J. Rheumatol., 1998, 25, 2298-2302.</p><p>Needleman P., Isacson P.C. The discovery and function of COX-2. J. Rheumatol., 1997, 24, 6-7.</p><p>Peterson W.L.,Cryer В.COX-1-SparingNSAIDs-is theenthusiasm justified? JAMA, 1999,282,1961-1963.</p><p>Singh G. Celecoxib use in patients: the spectrum and everyday experience. Satellite Symposium at the XV European League Against Rheumatism (ELTLAR) Congress, Nice, June 2000.</p><p>Singh G., Ramey D.R., Triadafilopoulos Experience with selective COX-2 inhibitors: safety profile in over 780000 patient years of use. XV European League Against Rheumatism (EULAR) Congress, Nice, June 2000 (abst.).</p><p>Simon L.S., Weaver A.L., Graham D.Y., et al. Antiinflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA, 1999, 282, 1921-1928.</p><p>Vane J. Towards a better aspirin. Nature, 1994, 367, 215-216.</p></div><br />
The authors declare that there are no conflicts of interest present.